BioSpace News Archive

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applications of their software programs were presented in poster form at the 2020 AASLD virtual Liver Meeting.

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round.

Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho RTI " or the " Company "), an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has completed a non-brokered private placement of secured non-convertible

Drawbridge Health and the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge (UK) today announced the use of the OneDraw™ Blood Collection Device1 for remote blood sample collection in a large-scale surveillance study currently being conducted to assess the prevalence of previous infection with COVID-19.

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, and affiliate company Acella Pharmaceuticals, LLC, have earned back-to-back annual recognition as the “Best Place to Work in Medical Sales: Small Pharma Category.” This announcement was made by MedReps, the leading job site for experienced industry professionals. In a

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced that its efforts to test and validate its patented Bio-RFID™ platform technology for non-invasive glucose monitoring with third-party research organizations have been temporarily slowed by the impact of Covid-19.

Oscar, the first health insurance company built around a full stack technology platform and a relentless focus on serving our members, today announced it has hired R. Scott Blackley as its new Chief Financial Officer, effective March 16, 2021.

PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will host a key opinion leader (KOL) call on D-PLEX100 for the prevention of surgical site infections on Tuesday, December 15, 2020, at 8:00 am Eastern Time.

Cold and flu season in the midst of a pandemic means that every sniffle, sneeze, sore throat and cough is suspected to be COVID-19. When symptoms strike, you need immediate answers

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price